Global Human Combination Vaccines Market 2017-2021
About Human Combination Vaccines
A vaccine is made up of inactive, partially killed or dead viruses, to stimulate the immune system against the pathogenic virus and produce antibodies against it. Vaccines are injected or orally administered. Animal vaccines provide immunity to the animal body against pathogens. They are composed of attenuated or dead virus strains and can be administered via the intramuscular, intradermal, or oral route. Similarly, human vaccines are composed of inactivated or live attenuated virus particles and provide immunity to the human body against different pathogens and can be administered via the intramuscular, intradermal, oral, and subcutaneous route. The modern human vaccines are mostly composed of inactivated virus strains.
Technavio’s analysts forecast the global Human Combination Vaccines market to grow at a CAGR of 8.56% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global Human Combination Vaccines market for 2017-2021. To calculate the market size, the report considers the sales of both branded and generic versions of human combination vaccines.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Human Combination Vaccines Market 2017-2021
Technavio recognizes the following companies as the key players in the global human combination vaccines market: GlaxoSmithKline, Merck, and Sanofi.
Other Prominent Vendors in the market are: Daiichi Sankyo, Serum Institute of India, and Takeda Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is government-sponsored programs. In the past, various diseases have been eradicated globally due to continuous efforts by governments to develop effective combination vaccines and implement proper immunization programs. Vaccines are the cornerstone of the fight against various communicable diseases, which can be proven by the success of smallpox eradication, the drastic decrease in polio cases during the past few decades, the progress toward tetanus eradication, and the decrease in measles mortality rate. Despite such initiatives, infectious diseases remain one of the major causes of deaths worldwide.”
According to the report, one of the major drivers for this market is rise in cases of infectious diseases. Infectious diseases are one of the most common causes of illnesses and deaths worldwide. The presence of microbes and their ability to multiply and adapt to changing populations, environments, and technologies create an ongoing threat to public health. In developing countries, the influence of infectious diseases is often devastating, leading to decreased survival rates, particularly in the pediatric population, and impeding opportunities for economic growth and development.
Further, the report states that one of the major factors hindering the growth of this market is requirement of cold chain logistics. Cold chain logistics required for the storage of vaccines is a key challenge hindering the growth of global human combination vaccine markets, leading to lower acceptability among end-users. Combination vaccines should be stored in cold temperatures to retain their efficacy. They are likely to lose potency if the temperature drops below 2°C or shoots above 8°C. Care should be taken to avoid storing vaccines at freezing temperature as it will destroy vaccines, making them unfit for use. This loss of effectiveness is irreversible, leading to wastage of vaccines and related resources.
GlaxoSmithKline, Merck, Sanofi, Daiichi Sankyo, Serum Institute of India, and Takeda Pharmaceuticals.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook